In CUPID STUDY B, IL-4 and IL-13 inhibitor Dupixent (dupilumab) wasn't able to achieve a significant improvement in symptoms in Xolair-refractory CSU patients, and will be stopped for futility ...

The first is dupilumab (Dupixent), approved by the FDA for use in atopic dermatitis in 2017 and asthma in 2018. In the phase III LIBERTY-CSU CUPID study, dupilumab improved symptom control ...

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut allergy was not achieved, according to study results. Image: Adobe Stock ...